Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials

Abstract

BACKGROUND: Evidence from randomised clinical trials (RCTs) of Janus kinase (JAK) inhibitors-compared with usual care or placebo-in adults treated in hospital for COVID-19 is conflicting. We aimed to evaluate the benefits and harms of JAK inhibitors compared with placebo or usual care and whether treatment effects differed between prespecified participant subgroups. METHODS: For this systematic review and individual participant data …

Authors

Amstutz A; Schandelmaier S; Ewald H; Speich B; Schwenke JM; Schönenberger CM; Schobinger S; Agoritsas T; Tomashek KM; Nayak S

Journal

The Lancet Respiratory Medicine, Vol. 13, No. 6, pp. 530–544

Publisher

Elsevier

Publication Date

June 2025

DOI

10.1016/s2213-2600(25)00055-4

ISSN

2213-2600

Associated Experts

Thomas Agoritsas

Assistant Professor (Part-Time), Faculty of Health Sciences

Visit profile

Labels